POSA110 Cost-Effectiveness Analysis of Pembrolizumab Versus Brentuximab Vedotin (BV) in Adult and Paediatric Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma in France
Abstract
Authors
R Minacori M Apert S Leproust R Monnier RO Casasnovas P Brice RH Borse J Gandhi A Rai